Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine/Carboplatin Followed by Paclitaxel in Advanced NSCLC
NCT00276588Phase 2Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Jul 2005
- Primary completion
- Mar 2007
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine, carboplatin and paclitaxel in non-small cell lung cancer (NSCLC), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoints: Response Rate, Median Survival and 6 more. Started Jul 2005; status: completed.
02
Drugs
gemcitabinecarboplatinpaclitaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00276588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00276588.